P0068 Hepatocellular carcinoma in Qatar

Rasul, Kakil Ibrahim; Al-Azawi, S.H.; Chandra, Preeti

doi:10.1016/j.ejca.2014.03.112

Cited by 4 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This higher incidence of HCV prevalence in Qatar is emphasized by the fact of a growing expatriate worker population from high prevalence region with HCV infection like Egypt and Pakistan. The fact that HCV and HBV are the underlying etiology for the development of HCC in Qatar was mentioned by Rasul et al [23]. Also, the presence of a background of liver cirrhosis in the present study has been high (83%), this is in accordance with most of the published literature [24].…”

Section: Discussionsupporting

confidence: 82%

The Role of Palliative Care in the Management of Patients with Advanced Hepatocellular Carcinoma: A Single Institution Experience

Ayman¹,

Ah²,

Yasser³

et al. 2017

J Pat Care

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 82%

The Role of Palliative Care in the Management of Patients with Advanced Hepatocellular Carcinoma: A Single Institution Experience

Ayman¹,

Ah²,

Yasser³

et al. 2017

J Pat Care

View full text Add to dashboard Cite

“…Possible mechanisms of T2D-associated increases in the risk of HCC may include indirect activation of insulin-like growth factor pathways, altering endogenous sex hormones, or chronic inflammation [ 14 , 34 , 35 ]. According to the most recent WHO reports, Egypt, Bahrain, Kuwait, Oman Saudi Arabia, and the UAE are among the ten countries in the world with the highest diabetes and prediabetes prevalence [ 13 , 14 , 15 , 17 ]. A recent retrospective study from a single center in Kuwait showed more than a third of the screened patients had T2D as a risk factor for HCC [ 14 ].…”

Section: Epidemiology Of Hcc Across the Gulf Regionmentioning

confidence: 99%

“…Recent data from the Cancer Registry of UAE have shown the incidence of HCC in non-UAE citizens has increased from almost twice in 2017 to almost thrice that of UAE citizens in 2019 [ 61 , 62 ]. The fact that HCC incidence is more common in males than females generally reflects the population structure of the Gulf countries, especially Kuwait and Qatar, where there are more males than females due to the presence of expatriate workers [ 13 , 14 , 15 , 17 , 63 , 64 ]. Among the resident nationals, the difference in HCC incidence between males and females is much less evident [ 13 , 14 , 15 , 17 , 63 , 64 ].…”

Section: Epidemiology Of Hcc Across the Gulf Regionmentioning

confidence: 99%

“…The fact that HCC incidence is more common in males than females generally reflects the population structure of the Gulf countries, especially Kuwait and Qatar, where there are more males than females due to the presence of expatriate workers [ 13 , 14 , 15 , 17 , 63 , 64 ]. Among the resident nationals, the difference in HCC incidence between males and females is much less evident [ 13 , 14 , 15 , 17 , 63 , 64 ]. The gradually increasing number of cases of HCC in the GCC region has put additional demands on the healthcare system, especially for clinical oncology services, particularly since most patients present with advanced-stage HCC.…”

Section: Epidemiology Of Hcc Across the Gulf Regionmentioning

confidence: 99%

“…Consequently, most patients present with an advanced stage of the disease [ 11 ]. The etiological differences among the population affected with HCC in the Gulf region make it imperative to develop and implement effective screening programs for early diagnosis and treatment to improve patient outcomes [ 13 , 14 , 15 , 16 , 17 , 18 ]. In this review, we discuss the available literature on the epidemiological factors, clinicopathological characteristics, screening practices, and management strategies for intermediate- and advanced-stage HCC in the Gulf region.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations

Albarrak

Al-Shamsi

2023

Cancers

View full text Add to dashboard Cite

The burden of hepatocellular carcinoma (HCC) is on the rise in the Gulf region, with most patients being diagnosed in the intermediate or advanced stages. Surgery is a treatment option for only a few, and the majority of patients receive either locoregional treatment (percutaneous ethanol injection, radiofrequency ablation, transarterial chemoembolization [TACE], radioembolization, radiotherapy, or transarterial radioembolization) or systemic therapy (for those ineligible for locoregional treatments or who do not benefit from TACE). The recent emergence of novel immunotherapies such as immune checkpoint inhibitors has begun to change the landscape of systemic HCC treatment in the Gulf. The combination of atezolizumab and bevacizumab is currently the preferred first-line therapy in patients not at risk of bleeding. Additionally, the HIMALAYA trial has demonstrated the superiority of the durvalumab plus tremelimumab combination (STRIDE regimen) therapy in efficacy and safety compared with sorafenib in patients with unresectable HCC. However, there is a lack of data on post-progression treatment after first-line therapy with either atezolizumab plus bevacizumab or durvalumab plus tremelimumab regimens, highlighting the need for better-designed studies for improved management of patients with unresectable HCC in the Gulf region.

show abstract

Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region

Waked,

Alsammany,

Tirmazy

et al. 2023

Liver International

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a growing health concern projected to cross over a million cases worldwide by 2025. HCC presents a significant burden of disease in Middle East and North African (MENA) countries due to a high prevalence of risk factors such as hepatitis C and B infections and rising incidence of non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease. In August 2022, an advisory meeting consisting of experts from 5 MENA countries was convened in an attempt to provide consensus recommendations on HCC screening, early diagnosis, current treatment modalities and unmet medical needs in the region. Data were collected from a pre‐meeting survey questionnaire and responses analysed and presented during the advisory meeting. This review summarizes the evidence discussed at the meeting and provides expert recommendations on the management of HCC. The 2022 update of Barcelona clinic liver cancer (BCLC) staging and treatment strategy and its implementation in the MENA region was extensively discussed. A key consensus of the expert panel was that multidisciplinary care is crucial to effective patient management that results in better clinical outcomes and overall survival of the patient. The panel recommended the use of predictive and early response biomarkers to guide clinicians in arriving at more effective therapeutic decisions. The experts also emphasized the role of robust screening/surveillance systems, population‐based registries, effective referral pathways and standardization of guidelines to ensure the successful management of HCC in the region.

show abstract

P0068 Hepatocellular carcinoma in Qatar

Cited by 4 publications

References 0 publications

The Role of Palliative Care in the Management of Patients with Advanced Hepatocellular Carcinoma: A Single Institution Experience

The Role of Palliative Care in the Management of Patients with Advanced Hepatocellular Carcinoma: A Single Institution Experience

Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations

Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region

Contact Info

Product

Resources

About